Instructions Thiotriazolin tablets 200 mg blister No. 90
Composition
active ingredient(s): thiazotic acid;
1 tablet contains morpholinium salt of thiazide acid in terms of 100% substance – 200 mg, which is equivalent to 133 mg of thiazide acid;
Excipients: potato starch, povidone, powdered sugar, microcrystalline cellulose, calcium stearate.
Dosage form
Pills.
Main physicochemical properties: white or almost white tablets, round in shape with a flat surface, with a bevel and a score.
Pharmacotherapeutic group
Cardiological drugs. Other cardiological drugs. Thiazide acid. ATX code C01E B23.
Pharmacological properties
Pharmacodynamics
The pharmacological effect of thiazide acid is due to its anti-ischemic, membrane-stabilizing, antioxidant, and immunomodulatory effects.
The effect of the drug is realized by enhancing the compensatory activation of anaerobic glycolysis and activation of oxidation processes in the Krebs cycle with the preservation of the intracellular ATP pool. The presence in the structure of the thiazolidinedione molecule of sulfur thiol, which is characterized by redox properties, and tertiary nitrogen, which binds excess hydrogen ions, causes the activation of the antioxidant system. The strong reducing properties of the thiol group cause a reaction with reactive oxygen species and lipid radicals. Reactivation of antiradical enzymes - superoxide dismutase, catalase and glutathione peroxidase - prevents the initiation of reactive oxygen species.
The effect of thiazide acid leads to inhibition of lipid oxidation processes in ischemic areas of the myocardium, reduction of myocardial sensitivity to catecholamines, prevention of progressive inhibition of cardiac contractile function, stabilization and reduction of the necrosis and ischemia zones of the myocardium, respectively. Improvement of the rheological properties of the blood is achieved by activating the fibrinolytic system. Improvement of myocardial metabolic processes, increase of its contractility, promotion of normalization of heart rhythm allow us to recommend thiazide acid for the treatment of patients with various forms of ischemic heart disease.
In parallel with the use of the drug in cardiology, thiazide acid is used in the treatment of diseases of the liver and other internal organs, given its high hepatoprotective properties. The drug prevents the destruction of hepatocytes, reduces the degree of fatty infiltration and the spread of centrilobular necrosis of the liver, promotes the processes of reparative regeneration of hepatocytes, normalizes protein, carbohydrate, lipid and pigment metabolism in them. Increases the rate of synthesis and secretion of bile, normalizes its chemical composition.
Pharmacokinetics
After oral administration, the drug is rapidly absorbed, its absolute bioavailability is 53%. The maximum concentration in blood plasma is reached 1.6 hours after a single dose of 200 mg. The half-life is almost 8 hours.
Indication
In the complex treatment of ischemic heart disease: angina pectoris, myocardial infarction, post-infarction cardiosclerosis; cardiac arrhythmias. In the complex treatment of chronic hepatitis of various etiologies, including alcoholic hepatitis; liver cirrhosis.
Contraindication
Hypersensitivity to thiazide acid and other components of the drug; acute renal failure.
Interaction with other medicinal products and other types of interactions
Thiotriazolin® as a cardioprotective drug can be used in combination with basic treatment agents for ischemic heart disease.
As a hepatoprotective agent, it can be combined with the prescription of traditional methods of treating hepatitis.
Application features
Missing.
Ability to influence reaction speed when driving vehicles or other mechanisms
There are currently no reports, but the possibility of dizziness should be considered.
Use during pregnancy or breastfeeding
The efficacy and safety of the drug during pregnancy or breastfeeding have not been studied.
Method of administration and doses
For stable angina pectoris, Thiotriazolin® is prescribed at a dose of 200 mg orally 3 times a day. The course of treatment is 8 weeks.
For angina pectoris at rest, myocardial infarction, and post-infarction cardiosclerosis, Thiotriazolin® should be administered at a dose of 200 mg orally 3 times a day for 20-30 days.
For heart rhythm disorders, Thiotriazolin® should be administered at a dose of 200 mg orally or sublingually 3 times a day.
For liver diseases, Thiotriazolin® should be prescribed at a dose of 200 mg orally 3 times a day for 20-30 days.
The duration of the treatment course is determined by the doctor individually depending on the severity and course of the disease.
Children
Experience with the use of the drug in children is insufficient.
Overdose
In case of overdose, the concentration of sodium and potassium in the urine increases.
In such cases, the drug must be discontinued.
Treatment is symptomatic.
Adverse reactions
The drug is usually well tolerated.
Skin and subcutaneous tissue disorders: itching, skin hyperemia, rash, urticaria, angioedema.
When taken as part of complex therapy, mainly in elderly patients, the following may occur:
from the immune system: anaphylactic shock;
from the central and peripheral nervous system: dizziness, tinnitus;
Gastrointestinal: dyspeptic symptoms, including dry mouth, nausea, vomiting; abdominal bloating;
from the respiratory system, chest organs and mediastinum: shortness of breath, wheezing;
general disorders: general weakness, fever.
During post-marketing surveillance, reactions were also observed, the relationship of which to the use of Thiotriazolin® has not been proven:
Cardiovascular system: arterial hypertension, tachycardia.
Expiration date
2 years.
Storage conditions
In the original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children.
Packaging
15 tablets in a blister, 6 blisters in a cardboard pack.
Vacation category
According to the recipe.
Producer
PJSC "Kyivmedpreparat".
Location of the manufacturer and its business address
Ukraine, 01032, Kyiv, Saksaganskoho St., 139.
